ATE502654T1 - Verfahren und zusammensetzungen zur behandlung von interferon-resistenten tumoren - Google Patents

Verfahren und zusammensetzungen zur behandlung von interferon-resistenten tumoren

Info

Publication number
ATE502654T1
ATE502654T1 AT04813611T AT04813611T ATE502654T1 AT E502654 T1 ATE502654 T1 AT E502654T1 AT 04813611 T AT04813611 T AT 04813611T AT 04813611 T AT04813611 T AT 04813611T AT E502654 T1 ATE502654 T1 AT E502654T1
Authority
AT
Austria
Prior art keywords
interferon
resistant tumors
compositions
methods
recombinant vectors
Prior art date
Application number
AT04813611T
Other languages
English (en)
Inventor
William Benedict
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Application granted granted Critical
Publication of ATE502654T1 publication Critical patent/ATE502654T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04813611T 2003-12-10 2004-12-10 Verfahren und zusammensetzungen zur behandlung von interferon-resistenten tumoren ATE502654T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52852503P 2003-12-10 2003-12-10
PCT/US2004/041307 WO2005058368A1 (en) 2003-12-10 2004-12-10 Methods and compositions for treatment of interferon-resistant tumors

Publications (1)

Publication Number Publication Date
ATE502654T1 true ATE502654T1 (de) 2011-04-15

Family

ID=34699875

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04813611T ATE502654T1 (de) 2003-12-10 2004-12-10 Verfahren und zusammensetzungen zur behandlung von interferon-resistenten tumoren

Country Status (16)

Country Link
US (7) US7691822B2 (de)
EP (2) EP2301584A1 (de)
JP (2) JP4801594B2 (de)
KR (1) KR101163248B1 (de)
CN (1) CN1893981B (de)
AT (1) ATE502654T1 (de)
AU (1) AU2004298991A1 (de)
BR (1) BRPI0417451A (de)
CA (1) CA2548100C (de)
DE (1) DE602004031973D1 (de)
ES (1) ES2363912T3 (de)
IL (1) IL175820A0 (de)
NO (1) NO20062385L (de)
SG (2) SG133594A1 (de)
WO (1) WO2005058368A1 (de)
ZA (1) ZA200604640B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
PT1456377T (pt) * 2001-12-20 2019-09-10 Merck Sharp & Dohme Composições de syn3 e processos
NZ543970A (en) * 2003-06-04 2008-09-26 Canji Inc Methods and compositions for interferon therapy
ATE502654T1 (de) * 2003-12-10 2011-04-15 Canji Inc Verfahren und zusammensetzungen zur behandlung von interferon-resistenten tumoren
WO2006065827A2 (en) 2004-12-13 2006-06-22 Canji, Inc. Cell lines for production of replication-defective adenovirus
EP1974044B1 (de) * 2005-12-12 2011-01-26 CANJI, Inc. Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
US20070231301A1 (en) * 2006-03-31 2007-10-04 Warren Stephen L Parenteral low dose type 1 interferons for bladder cancer
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
AU2013317805B2 (en) 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
CA3014759C (en) * 2016-02-15 2020-09-22 FKD Therapies Limited Improved interferon therapy
US11311487B2 (en) * 2016-04-14 2022-04-26 Trizell Ltd. Viral vector stabilization
TW201924722A (zh) * 2017-12-05 2019-07-01 美商Ｐｄｓ生技公司 用於刺激第i型干擾素基因之方法及包含陽離子脂質的組合物
CN111363726A (zh) * 2018-12-26 2020-07-03 上海元宋生物技术有限公司 表达干扰素的溶瘤病毒及其应用
US20200222477A1 (en) * 2019-01-10 2020-07-16 Trizell Ltd. Method to Curtail the Progression of Non-Muscle Invasive Bladder Cancer To Muscle-Invasive Cancer
CN115484985A (zh) 2020-03-19 2022-12-16 崔泽尔有限公司 温度响应病毒储存系统
KR20230012471A (ko) * 2020-03-30 2023-01-26 트리젤 엘티디. 암 치료용 조성물 및 방법

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5618711A (en) * 1986-08-22 1997-04-08 Hoffmann-La Roche Inc. Recombinant expression vectors and purification methods for Thermus thermophilus DNA polymerase
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0331635A3 (de) 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Zubereitungen zur Behandlung von Blasenkrebs.
US6207454B1 (en) 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US5120316A (en) 1990-09-28 1992-06-09 Akzo N.V. Urethral catheter and catheterization process
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
JPH10507758A (ja) * 1994-10-19 1998-07-28 ジェネティック セラピー，インコーポレイテッド アデノウイルスおよび免疫抑制剤同時反復投与を伴う遺伝子治療
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
WO1997005209A1 (en) 1995-07-28 1997-02-13 Kohne David E Method for enhancing chemiluminescence
US20040014709A1 (en) 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
IL129387A0 (en) 1996-10-18 2000-02-17 Canji Inc Methods and compositions for delivery and expression of interferon-alpha nucleic acids
US6210969B1 (en) * 1999-04-28 2001-04-03 Coulter International Corp. Composition and method for differentiation of basophil and eosinophil subpopulations of leukocytes in blood
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
PT1456377T (pt) 2001-12-20 2019-09-10 Merck Sharp & Dohme Composições de syn3 e processos
US20040076622A1 (en) * 2002-03-02 2004-04-22 Board Of Regents, The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
NZ543970A (en) * 2003-06-04 2008-09-26 Canji Inc Methods and compositions for interferon therapy
AU2004245074A1 (en) 2003-06-04 2004-12-16 Canji, Inc Methods and compositions for interferon therapy
ATE502654T1 (de) 2003-12-10 2011-04-15 Canji Inc Verfahren und zusammensetzungen zur behandlung von interferon-resistenten tumoren
EP1974044B1 (de) 2005-12-12 2011-01-26 CANJI, Inc. Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase

Also Published As

Publication number Publication date
EP1691844B1 (de) 2011-03-23
US9439977B2 (en) 2016-09-13
AU2004298991A1 (en) 2005-06-30
NO20062385L (no) 2006-09-05
US20190374654A1 (en) 2019-12-12
EP2301584A1 (de) 2011-03-30
US20200164091A1 (en) 2020-05-28
DE602004031973D1 (de) 2011-05-05
CA2548100C (en) 2015-03-24
CN1893981B (zh) 2011-03-23
ZA200604640B (en) 2007-04-25
ES2363912T3 (es) 2011-08-19
SG133594A1 (en) 2007-07-30
KR101163248B1 (ko) 2012-07-05
IL175820A0 (en) 2006-10-05
US7691822B2 (en) 2010-04-06
US20050287119A1 (en) 2005-12-29
KR20060127397A (ko) 2006-12-12
CA2548100A1 (en) 2005-06-30
CN1893981A (zh) 2007-01-10
US20210322572A1 (en) 2021-10-21
EP1691844A4 (de) 2007-11-28
WO2005058368A1 (en) 2005-06-30
EP1691844A1 (de) 2006-08-23
BRPI0417451A (pt) 2007-04-10
HK1095525A1 (en) 2007-05-11
US20160045618A1 (en) 2016-02-18
US20100266547A1 (en) 2010-10-21
SG166117A1 (en) 2010-11-29
JP2007513963A (ja) 2007-05-31
US20240000968A1 (en) 2024-01-04
JP2011148834A (ja) 2011-08-04
JP4801594B2 (ja) 2011-10-26

Similar Documents

Publication Publication Date Title
DE602004031973D1 (de) Verfahren und zusammensetzungen zur behandlung von interferon-resistenten tumoren
DE122012000007I1 (de) Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung.
ATE493433T1 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
DE602005019144D1 (de) Verfahren zur schmerzbehandlung in knochenkrebs du
DE60335997D1 (de) Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
DE69434594D1 (de) Rekombinante adenoviren-vektor und verfahren zur verwendung
DE602004026867D1 (de) Rekombinanter adeno-assoziierter virusvektor zur behandlung von morbus alzheimer
ATE530560T1 (de) Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
ATE454396T1 (de) Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure
ATE453405T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
DE60237635D1 (de) Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
CY1107439T1 (el) Μεθοδοι προληψης και θεραπειας μολυνσης απο ιο του γενους flavivirus σε ζωα
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
ATE545658T1 (de) Verfahren zur behandlung von synovialsarkom
DE60319103D1 (de) Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten
ATE506370T1 (de) Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen
DE602004015142D1 (de) Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
DE60208534D1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle
EP1734827A4 (de) Verfahren und zusammensetzungen zur behandlung von mit anomaler mikrosatellitenexpansion in verbindung stehenden krankheiten
DE60239450D1 (de) Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
DE602004028239D1 (de) Protease, für die protease codierende dna und verfahren zur herstellung der protease
ATE345352T1 (de) Zusammensetzung einer parvovirus vp1- proteinvariante und eines arvovirus ns1-proteins zur induktion von zytolyse
ATE483030T1 (de) Neue polynukleotid- und polypeptidsequenzen und deren verwendungen
EP1566386A4 (de) Gen in zusammenhang mit haarausfall, das davon kodierte polypeptid und anwendungen dafür

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties